01419nas a2200205   4500000000100000000000100001008004100002260001200043653001300055653003600068653001700104100002000121700002100141245007800162856005500240300001200295490000700307520088500314022001401199       2021                            d  c2021-1010aGenetics10aGenome-wide association studies10aTherapeutics1 aWilliam R. Reay1 aMurray J. Cairns00aAdvancing the use of genome-wide association studies for drug repurposing  uhttps://www.nature.com/articles/s41576-021-00387-z  a658-6710 v223 aGenome-wide association studies (GWAS) have revealed important biological insights into complex diseases, which are broadly expected to lead to the identification of new drug targets and opportunities for treatment. Drug development, however, remains hampered by the time taken and costs expended to achieve regulatory approval, leading many clinicians and researchers to consider alternative paths to more immediate clinical outcomes. In this Review, we explore approaches that leverage common variant genetics to identify opportunities for repurposing existing drugs, also known as drug repositioning. These approaches include the identification of compounds by linking individual loci to genes and pathways that can be pharmacologically modulated, transcriptome-wide association studies, gene-set association, causal inference by Mendelian randomization, and polygenic scoring.  a1471-0064